Significance of qualitative PCR detection method for preemptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation - Single-centre experience

Neoplasma

Volumn 52, Issue 2, 2005, Pages 137-142

  Skapova D ^a   Racil Z ^a   Dvorakova D ^a   Minarikova D ^a   Mayer, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus; Polymerase chain reaction

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; VIRUS DNA;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; INFECTION PREVENTION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MONITORING; POLYMERASE CHAIN REACTION; QUALITATIVE ANALYSIS; RECURRENT INFECTION; VIRUS REACTIVATION;

EID: 17044439422     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. AVERY RK, ADAL KA, LONGWORTH DL, BOLWELL BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26: 763-767.
2. BOECKH M, BOWDEN RA, GOODRICH JM, PETTINGER M, MEYERS JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogenic marrow transplantation. Blood 1992; 80: 1358-1364.
3. BOECKH M, GOOLEY TA, MYERSON D, CUNNINGHAM T, SCHOCH G et al. Cytomegalovirus pp65 antigenemia - guided early treatment with ganciclovir versus ganciclovir at engraftment after allogenic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
4. BOECKH M, GALLEZ-HAWKINS GM, MYERSON D, ZAIA JA, BOWDEN RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogenic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-113.
5. BOECKH M, HUANG M, FERRENBERG J, STEVENS-AYERS T, STENSLAND L et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42: 1142-1148.
6. BOIVIN G, BELANGER R, DELAGE R, BELIVEAU C, DEMERS C et al. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 2000; 38: 4356-4360.
7. BOWDEN RA, SLIGHTER SJ, SAYERS M, WEISDORF D, CAYS M et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 1995; 85: 3598-3603.
8. BROERS AE, VAN DER HOLT R, VAN ESSER JW, GRATAMA JW, HENZEN-LOGMANS S et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-2245.
9. CORTEZ KJ, FISCHER SH, FAHLE GA, CALHOUN LB, CHILDS RW et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis 2003; 188: 967-972.
10. DE MEDEIROS CR, MOREIRA VA, PASQUINI R. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation. Bone Marrow Transplant 2000; 26: 443-444.
11. EHRNST A, BARKHOLT L, LEWENSOHN-FUCHS I, LJUNGMAN P, TEODOSIU O et al. CMV PCR monitoring in leucocytes of transplant patients. Clin Diagn Virol 1995; 3: 139-153.
12. EINSELE H, EHNINGER G, HEBART H, WITTKOWSKI KM, SCHULER U et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
13. FLEXMAN J, KAY I, FONTE R, HERRMANN R, GABBAY E et al. Differences between the quantitative antigenemia assay and the cobas amplicor monitor quantitative PCR assay for detecting CMV viraemia in bone marrow and solid organ transplant patients. J Med Virol 2001; 64: 275-282.
14. GILBERT C, ROY J, BELANGER R, DELAGE R, BELIVEAU C et al. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 2001; 45: 3669-3671.
15. GRISCELLI F, BARROIS M, CHAUVIN S, LASTERE S, BELLET D et al. Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J Clin Microbiol 2001; 39: 4362-4369.
16. GRUNDY JE, EHRNST A, EINSELE H, EMERY VC, HEBART H et al. A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood. J Clin Microbiol 1996; 34: 1166-1170.
17. KAISER L, PERRIN L, CHAPUIS B, HADAYA K, KOLAROVA L et al. Improved monitoring of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation by an ultrasensitive plasma DNA PCR assay. J Clin Microbiol 2002; 40: 4251-4255.
18. KANDA Y, MINEISHI S, SAITO T, SEO S, SAITO A et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444.
19. LI H, DUMMER JS, ESTES WR, MENG S, WRIGHT PF et al. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol 2003; 41: 187-191.
20. LJUNGMAN P, LORE K, ASCHAN J, KLAESSON S, LEWENSOHN-FUCHS I et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
21. LJUNGMAN P, OBERG G, ASCHAN J, EHRNST A, LONNQVIST B et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 18: 565-568.
22. MACHADO CM, DULLEY FL, BOAS LS, CASTELLI JB, MACEDO MC et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000; 26: 413-417.
23. MACHADO CM, MENEZES RX, MACEDO MC, MENDES AV, BOAS LS et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28: 1053-1059.
24. MAYER J, KRAHULOVA M, VORLICEK J. Prophylaxis of the early complications associated with allogenic transplantation of peripheral blood or bone marrow progenitors cells. Klin Onkol 1997; 4: 110-115 (in Czech).
25. MAYER J, DVORAKOVA D, KRAHULOVA M, VORLICEK J, ADLER J. Diagnosis of cytomegalovirus infection with the polymerase chain reaction and antigenemia in patients after allogenic peripheral stem cell transplantation-comparison of 318 paired samples. Cas Lek Cesk 1999; 138: 436-440 (in Czech).
26. MORI T, OKAMOTO S, WATANABE R, YAJIMA T, IWAO Y et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 777-782.
27. NICHOLSON VA, WHIMBEY E, CHAMPLIN R, ABI-SAID D, PRZEPIORKA D et al. Comparison of cytomegalovirus antigenemia and shell vial culture in allogenic marrow transplantation recipients receiving ganciclovir prophylaxis. Bone Marrow Transplant 1997; 19: 37-41.
28. PEGGS KS, PREISER W, KOTTARIDIS PD, MCKEAG N, BRINK NS et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782-790.
29. PORTER-JORDAN K, ROSENBERG EI, KEISER JF, GROSS JD, ROSS AM et al. Nested polymerase chain reaction assay for the detection of cytomegalovirus overcomes false positives caused by contamination with fragmented DNA. J Med Virol 1990; 30: 85-91.
30. PREISER W, BRAUNINGER S, SCHWERDTFEGER R, AYLIFFE U, GARSON JA et al. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol 2001; 20: 59-70.
31. PREISER W, BRINK NS, AYLIFFE U, PEGGS KS, MACKINNON S et al. Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma. J Clin Virol 2003; 26: 49-59.
32. PRENTICE HG, GLUCKMAN E, POWLES RL, LJUNGMAN P, MILPIED N et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogenic bone marrow transplantation. Lancet 1994; 343: 749-753.
33. QAMRUDDIN AO, OPPENHEIM BA, GUIVER M, MUTTON KJ, CHOPRA R. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant 2001; 27: 301-306.
34. SCHULENBURG A, WATKINS-RIEDEL T, GREINIX HT, RABITSCH W, LOIDOLT H et al. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant 2001; 28: 765-768.
35. SINGH N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742-751.
36. SINGHAL S, MEHTA J, POWLES R, TRELEAVEN J, HORTON C et al. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 777-781.
37. TANAKA N, KIMURA H, IIDA K, SAITO Y, TSUGE I et al. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J Med Virol 2000; 60: 455-462.
38. VAN DER BIJ W, SCHIRM J, TORENSMA R, WILLEM J, VAN SON WJ et al. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26: 2531-2535.
39. VAN DER BIJ W, TORENSMAR, VAN SON WJ, ANEMA J, SCHIRM J et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988; 25: 179-188.
40. VAN DER BIJ W, VAN DIJK RB, VAN SON WJ, TORENSMA R, PRENGER KB et al. Antigen test for early diagnosis of active cytomegalovirus infection in heart transplant recipients. J Heart Transplant 1988; 7: 106-109.
41. VON MULLER L, HAMPL W, HINZ J, MEISEL H, REIP A et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002; 40: 2285-2287.
42. WEINBERG A, SCHISSEL D, GILLER R. Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol 2002; 40: 4203-4206.
43. YUN Z, LEWENSOHN-FUCHS I, LJUNGMAN P, VAHLNE A. Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays. Transplantation 2000; 69: 1733-1736.
44. ZAIA JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002; 35: 999-1004.